Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
Early human immunodeficiency virus type 1 (HIV-1) treatment during the acute period of infection can significantly limit the seeding of viral reservoirs and modify the course of disease. However, while a number of HIV-1 broadly neutralizing antibodies (bnAbs) have demonstrated remarkable efficacy as prophylaxis in macaques chronically infected with simian-human immunodeficiency virus (SHIV), intriguingly, their inhibitory effects were largely attenuated in the acute period of SHIV infection. To investigate the mechanism for the disparate performance of bnAbs in different periods of SHIV infection, we used LSEVh-LS-F, a bispecific bnAb targeting the CD4 binding site and CD4-induced epitopes, as a representative bnAb and assessed its potential therapeutic benefit in controlling virus replication in acutely or chronically SHIV-infected macaques. We found that a single infusion of LSEVh-LS-F resulted in rapid decline of plasma viral loads to undetectable levels without emergence of viral resistance in the chronically infected macaques. In contrast, the inhibitory effect was robust but transient in the acutely infected macaques, despite the fact that all macaques had comparable plasma viral loads initially. Infusing multiple doses of LSEVh-LS-F did not extend its inhibitory duration. Furthermore, the pharmacokinetics of the infused LSEVh-LS-F in the acutely SHIV-infected macaques significantly differed from that in the uninfected or chronically infected macaques. Host SHIV-specific immune responses may play a role in the viremia-dependent pharmacokinetics. Our results highlight the correlation between the fast clearance of infused bnAbs and the treatment failure in the acute period of SHIV infection and may have important implications for the therapeutic use of bnAbs to treat acute HIV infections.IMPORTANCE Currently, there is no bnAb-based monotherapy that has been reported to clear the virus in the acute SHIV infection period. Since early HIV treatment is considered critical to restricting the establishment of viral reservoirs, investigation into the mechanism for treatment failure in acutely infected macaques would be important for the therapeutic use of bnAbs and eventually towards the functional cure of HIV/AIDS. Here we report the comparative study of the therapeutic efficacy of a bnAb in acutely and chronically SHIV-infected macaques. This study revealed the correlation between the fast clearance of infused bnAbs and treatment failure during the acute period of infection.
['Wu|Yanling|Y|', 'Xue|Jing|J|', 'Wang|Chunyu|C|', 'Li|Wei|W|', 'Wang|Lili|L|', 'Chen|Weizao|W|', 'Prabakaran|Ponraj|P|', 'Kong|Desheng|D|', 'Jin|Yujia|Y|', 'Hu|Dan|D|', 'Wang|Yulu|Y|', 'Lei|Cheng|C|', 'Yu|Diao|D|', 'Tu|Chao|C|', 'Bardhi|Ariola|A|', 'Sidorov|Igor|I|', 'Ma|Liying|L|', 'Goldstein|Harris|H|', 'Qin|Chuan|C|', 'Lu|Lu|L|', 'Jiang|Shibo|S|', 'Dimitrov|Dimiter S|DS|', 'Ying|Tianlei|T|']
D000818:Animals D000914:Antibodies, Viral D000998:Antiviral Agents D000080908:Broadly Neutralizing Antibodies D054884:Host-Pathogen Interactions D008253:Macaca mulatta D016097:Simian Acquired Immunodeficiency Syndrome D015302:Simian Immunodeficiency Virus
broadly neutralizing antibodies HIV-1 acute SHIV infection